Clinical and Biological Basis of Lung Cancer Prevention

1. Prevention and Early Detection of Lung Cancer - Clinical Aspects.- 2. Smoking Prevention and Cessation.- 3. Clinical Pharmacology of Vitamin A and Retinoids.- 4. Early Lung Cancer Detection.- 5. Molecular Abnormalities in the Sequential Development of Lung Carcinoma.- 6. Application of In Situ PCR and In Situ Hybridization to the Characterization of Lung Cancers.- 7. Tumor Stroma Formation in Lung Cancer.- 8. Tumor Angiogenesis: Basis for New Prognostic Factors and New Anticancer Therapies.- 9. Cell Cycle Regulators and Mechanisms of Growth Control Evasion in Lung Cancer.- 10. Molecular Genetics of Lung Cancer.- 11. Neuropeptides, Signal Transduction and Small Cell Lung Cancer.- 12. In Vitro Analysis of Bombesin/Gastrin-Releasing Peptide Receptor (bb2) Ligand Binding and G-Protein Coupling.- 13. DNA Methylation Changes in Lung Cancer.- 14. K-ras Mutations as Molecular Markers of Lung Cancer.- 15. Sheep Lung Adenomatosis: A Model of Virally Induced Lung Cancer.- 16. Retinoic Acid Receptor ß An Exploration of its Role in Lung Cancer Suppression and its Potential in Cancer Prevention.- 17. Cytochrome P450 Polymorphisms: Risk Factors for Lung Cancer?.- 18. Glutathione S-Transferases and Lung Cancer Risk.- 19. The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis.- 20. Endoscopic Localization of Preneoplastic Lung Lesions.- 21. Antigen Retrieval Improves hnRNP A2/B1 Immunohisto-chemical Localization in Premalignant Lesions of the Lung.- 22. Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer.- 23. Chemoprevention of Lung Cancer.- 24. Regional Delivery of Retinoids: A New Approach to Early Lung Cancer Intervention.- 25. Natural Inhibitors of Carcinogenesis.- 26. Gene Delivery to Airways.- 27. Lung Cancer Prevention: The Point of View of a Public Health Epidemiologist.- 28. Biomarkers as Intermediate Endpoints in Chemoprevention Trials: Biological Basis of Lung Cancer Prevention.- 29. Biological Tools for Mass Screening.- 30. Optimization of the Use of Biological Samples for the Prospective Evaluation of Preneoplastic Lesions.